News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|September 30, 2024

Early Diagnosis and Management, Unmet Needs and Treatment Challenges in Pediatric Plaque Psoriasis

Author(s)Karan Lal, DO, MS, FAAD, Helen T Shin, MD

Karan Lal, DO, and Helen T Shin, MD, discuss how early diagnosis of pediatric plaque psoriasis significantly improves management strategies and enhances long-term outcomes by allowing for timely intervention and personalized treatment plans.

Episodes in this series

2 KOLs are featured in this series.

EP. 1 Psychosocial Impact of Plaque Psoriasis in Younger Children

2 KOLs are featured in this series.

EP. 2 Overview of the Prevalence of Pediatric Plaque Psoriasis

2 KOLs are featured in this series.

EP. 3 Navigating Treatment Algorithms: Balancing Provider Preferences and Clinical Guidelines

2 KOLs are featured in this series.

EP. 4 Diagnostic Challenges in the Management of Pediatric Plaque Psoriasis

2 KOLs are featured in this series.

EP. 5 Adult vs Pediatric Plaque Psoriasis Treatment Challenges

2 KOLs are featured in this series.

EP. 6 Early Diagnosis and Management, Unmet Needs and Treatment Challenges in Pediatric Plaque Psoriasis

2 KOLs are featured in this series.

EP. 7 Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis

2 KOLs are featured in this series.

EP. 8 Exploring the Role of MOA and PDE4 Pathways in Pediatric Patients with Plaque Psoriasis

2 KOLs are featured in this series.

EP. 9 Provider Aspirations for Future Treatments and Clinical Investigations into Pediatric Plaque Psoriasis

EP. 10 Facing Challenges in Pediatric Plaque Psoriasis

EP. 10 Facing Challenges in Pediatric Plaque Psoriasis

Video content above is prompted by the following:

How does early diagnosis impact the management and long-term outcomes of pediatric plaque psoriasis? (Herbert, 2023)

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Clinical Pearls for Management of Pediatric Atopic Dermatitis With Topicals

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Therapy Gaps in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Counseling Caregivers in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 14th 2025

Escalating to Systemic Therapies in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 14th 2025

Long-Term Strategies and New Horizons for Managing Facial Hyperpigmentation

ByMarie Bosslett, Assistant Editor

November 11th 2025

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Transformative Advances This Year and Beyond

FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol

Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control

"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions

Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population

© 2025 MJH Life Sciences^®

All rights reserved.